Today's Rundown Trump orders 'genius' biotechs to British PM's bedside More than 700 Henry Ford Health workers tested positive for COVID-19 As millions lose their jobs—and insurance—Bristol Myers, Eli Lilly expand patient assistance U.S., India spar over antimalarial as COVID-19 highlights state actor role in supply chain Healthcare roundup: Lyft grows access to non-emergency transport; Tyto Care raises $50M as demand for virtual care soars Biopharma roundup: AbbVie's Kaletra shows promise in early test; Lilly shareholder meeting goes virtual AMA President Harris calls for all governors to implement physical distancing guidelines KFF: Treating uninsured COVID-19 patients could cost as much as $41B U.S. government funds OraSure's at-home spit test for coronavirus infections To avoid DTC dips and communication snafus, pharma marketing shifts amid COVID-19 crisis Wellcome targets $8B raise in weeks to fix COVID-19 funding gap AHIP calls for CMS to delay mandatory new Medicare Advantage requirements due to COVID-19 Johnson & Johnson posts 'temporary' Tylenol shortage amid heightened demand Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report Featured Story | | | Tuesday, April 7, 2020 President Donald Trump has asked “leading” U.S. pharmaceutical companies working on experimental COVID-19 treatments to “contact London” and offer help to U.K. Prime Minister Boris Johnson, who is in intensive care after testing positive for the novel coronavirus last month. |
|
|---|
|
Top Stories Tuesday, April 7, 2020 A top physician at Henry Ford Health System says 734 workers have been infected with COVID-19. Tuesday, April 7, 2020 Aside from its devastating health consequences, the COVID-19 pandemic has left millions of Americans without work—and therefore without health insurance. Now, two Big Pharmas are expanding their assistance programs to help patients stay on their meds. Tuesday, April 7, 2020 President Donald J. Trump's endorsement of antimalarial hydroxychloroquine to treat COVID-19 has sent demand for the drug skyrocketing. But a tussle with India, a major U.S. drug supplier, over an export ban has added new concerns about the role of state actors in the global supply chain. Tuesday, April 7, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Tuesday, April 7, 2020 An early trial of AbbVie's Kaletra showed promise, while Eli Lilly is moving to a virtual shareholder meeting. And former FDA commissioner Scott Gottlieb has ideas about how the U.S. can prepare to move past the pandemic. Tuesday, April 7, 2020 American Medical Association President Patrice Harris called on governors who have not already implemented physical distancing in their states to do so immediately. Tuesday, April 7, 2020 The Trump administration’s pledge to reimburse hospitals for treating uninsured patients of COVID-19 could cost up to $41.8 billion, nearly half of the $100 billion given to hospitals in a recent economic stimulus package. Tuesday, April 7, 2020 BARDA funded the development of a rapid coronavirus test that can be self-administered at home. Designed by OraSure Technologies, the test would not only detect the novel infection that causes COVID-19 but all coronaviruses that can lead to severe respiratory disease. Tuesday, April 7, 2020 Pharma marketing, like the rest of the ad industry, is in a state of flux brought on by the COVID-19 pandemic. Concerns and debates are swirling around whether drug ads should scale back, if drugmakers should change messaging to be more serious or if they should delay DTC drug launch campaigns. Tuesday, April 7, 2020 Wellcome is calling on businesses to invest in an $8 billion (€7 billion) fund focused on reducing cases of COVID-19 to zero as soon as possible. Almost half the money is earmarked for the development of drugs and vaccines that Wellcome sees as the “world’s best exit strategy” from the pandemic. Tuesday, April 7, 2020 AHIP wants CMS to give insurers a reprieve from any new requirements in 2021 for Medicare Advantage to help them deal with the impact of COVID-19. Tuesday, April 7, 2020 With anxiety about the U.S. drug supply running high these days, drugmakers are keeping a close eye on demand spikes. Now, Johnson & Johnson, maker of ubiquitous painkiller Tylenol, is reporting shortages in certain markets as consumers stock their medicine chests. Tuesday, April 7, 2020 The race for a COVID-19 therapeutic has attracted many of the biggest names in biopharma, and now Alexion is getting ready to place a bet on its own Soliris, GlobalData reports. |
